Literature DB >> 17546670

Cardiomyopathy in Friedreich's ataxia-assessment by cardiac MRI.

Chris Meyer1, Gebhard Schmid, Sabine Görlitz, Monika Ernst, Christian Wilkens, Inga Wilhelms, Peter H Kraus, Peter Bauer, Jürgen Tomiuk, Horst Przuntek, Andreas Mügge, Ludger Schöls.   

Abstract

Cardiomyopathy is an important and frequently life limiting manifestation of Friedreich's ataxia (FA), the most prevalent form of autosomal recessive ataxia. Left ventricular mass is used as primary outcome measure in recent intervention studies but systematic analyses of FA cardiomyopathy are sparse. To assess cardiac hypertrophy by cardiac magnetic resonance imaging (MRI) in vivo, we assessed 41 adult patients with genetically confirmed FA and 33 age- and sex-matched healthy controls by cardiac MRI and echocardiogarphy. Septal hypertrophy and left ventricular mass index were determined by two independent raters. MRI revealed hypertrophy of the interventricular septum in 40% and increased left ventricular mass index in 29% of patients. Interobserver variability was less than 5% for both measures. GAA repeat length had only minor influence on interventricular septum thickness. Left ventricular mass index decreased with age. Severity of ataxia did not correlate with cardiac disease. In echocardiography wall diameter was assessable only in 31 of 41 FA patients with 32% of patients presenting septal hypertrophy and 6% increased left ventricular mass index. We conclude that cardiac hypertrophy is present only in a minority of adult FA patients. If despite this limitation intervention studies use left ventricular mass as outcome measure, MRI is recommended as the most accurate assessment of cardiac anatomy in vivo. Copyright (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17546670     DOI: 10.1002/mds.21590

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  16 in total

Review 1.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

Authors:  Praveen G Ranganath; Albree Tower-Rader
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 2.  Friedreich's ataxia: pathology, pathogenesis, and molecular genetics.

Authors:  Arnulf H Koeppen
Journal:  J Neurol Sci       Date:  2011-04-15       Impact factor: 3.181

3.  Common data elements for clinical research in Friedreich's ataxia.

Authors:  David R Lynch; Massimo Pandolfo; Jorg B Schulz; Susan Perlman; Martin B Delatycki; R Mark Payne; Robert Shaddy; Kenneth H Fischbeck; Jennifer Farmer; Paul Kantor; Subha V Raman; Lisa Hunegs; Joanne Odenkirchen; Kristy Miller; Petra Kaufmann
Journal:  Mov Disord       Date:  2012-12-12       Impact factor: 10.338

Review 4.  [Heart involvement in Friedreich's ataxia].

Authors:  F Weidemann; F Scholz; C Florescu; D Liu; K Hu; S Herrmann; G Ertl; S Störk
Journal:  Herz       Date:  2014-05-23       Impact factor: 1.443

5.  Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.

Authors:  Daniel Velasco-Sánchez; Asuncion Aracil; Raquel Montero; Ana Mas; Lorenzo Jiménez; Mar O'Callaghan; Maria Tondo; Antoni Capdevila; Josep Blanch; Rafael Artuch; Mercedes Pineda
Journal:  Cerebellum       Date:  2011-03       Impact factor: 3.847

6.  Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.

Authors:  Subha V Raman; Kavita Phatak; J Chad Hoyle; Michael L Pennell; Beth McCarthy; Tam Tran; Thomas W Prior; John W Olesik; Anthony Lutton; Chelsea Rankin; John T Kissel; Roula Al-Dahhak
Journal:  Eur Heart J       Date:  2010-12-14       Impact factor: 29.983

7.  Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 2: Rare phenotypes.

Authors:  Ailbhe C O'Neill; Shaunagh McDermott; Carole A Ridge; David Keane; Jonathan D Dodd
Journal:  World J Cardiol       Date:  2012-05-26

Review 8.  Evaluating the progression of Friedreich ataxia and its treatment.

Authors:  Martin B Delatycki
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

Review 9.  Diagnosis and treatment of Friedreich ataxia: a European perspective.

Authors:  Jörg B Schulz; Sylvia Boesch; Katrin Bürk; Alexandra Dürr; Paola Giunti; Caterina Mariotti; Francoise Pousset; Ludger Schöls; Pierre Vankan; Massimo Pandolfo
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

10.  Low-dose idebenone treatment in Friedreich's ataxia with and without cardiac hypertrophy.

Authors:  C Rinaldi; T Tucci; S Maione; A Giunta; G De Michele; A Filla
Journal:  J Neurol       Date:  2009-04-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.